Message from Martin Roche, MD
Holy Cross Hospital, Ft. Lauderdale, FL
I’ve just returned, like many of you, from yet another outstanding Academy meeting with over 12,000 HCPs in attendance. This year, more exhibitors and attendees than ever were discussing “robotic” joint replacement. Having performed the first sensor assisted and robotic assisted knee surgery in the world more than 12 years ago, it is exciting that robotics has evolved from an innovative technology to a solid platform that is being adopted by an increasing number of joint surgeons1.
While at the meeting, I had the pleasure of presenting at Stryker’s lunch symposium, “The potential clinical and economic benefits of Mako Robotic-Arm Assisted Surgery”. The event was chaired by Dr. Wael Barsoum from West Palm Beach, FL, and my co-presenters were Dr. Benjamin Domb, Hinsdale, IL, and Dr. Ormonde Mahoney, Athens, GA, and the meeting, of course, featured lots of compelling content.
Dr. Domb discussed how outpatient THA has the potential to be cost-effective2, and, based on his experience, robotics may improve patient outcomes at two and five years following surgery. Dr. Mahoney’s talk focused on his use of the Mako System, which he’s found to demonstrate enhanced planning3, dynamic joint balancing and kinematic assessment4, accurate bone preparation to plan5, and better prediction of implant sizes than 2D templating6. Dr. Mahoney also touched upon Professor Fares Haddad’s work across two distinct, prospective, consecutive series, single-surgeon studies comparing patients undergoing conventional jig-based total knee replacement versus Mako Total Knee surgery (40 patients7 and 30 patients8 in each cohort). The studies concluded that Mako Total Knee with Triathlon was associated with: less bone and soft tissue damage8 (p<0.05), less need for opiate analgesics6 (p<0.001), less time to hospital discharge7 (26% reduction in LOS), less need for in-patient physical therapy sessions6 (p<0.001), and less post-operative pain7 (p<0.001).
Finally, I spoke about why I expanded my Mako Partial Knee practice and why I consider unicompartmental knee arthroplasty a longer-term procedure vs. an interim one. In the appropriately indicated patients, Mako Partial Knee has been shown to have a higher forgotten joint score vs. TKA (2.5-year follow-up)9, less physical therapy vs. TKA10, reduced post-op pain vs. manual Oxford UKA (day 1 to week 8 post-op)11, decreased analgesia requirements vs. manual Oxford UKA12, shorter time to straight leg raise vs. manual Oxford UKA12, fewer PT sessions (5) vs. manual Oxford UKA (9)12, quicker hospital discharge vs. manual Oxford UKA12, and high patient satisfaction (5.7-year follow-up)13.
This year’s scientific exhibits, posters and podium presentations were extremely powerful, and included a strong presence of ten Mako robotic-themed acceptances, too. Acceptances featuring Stryker’s implant products alone included six knee and five hip related topics. In case you missed them at the meeting, here’s a summary of my top picks. And, in case you’re not aware, you can find all of the posters that were displayed at the meeting on the Academy’s website.
The results of this study demonstrated that patients who underwent rUKA had fewer revision procedures, shorter LOS, and incurred lower mean costs at 24-months. These results are likely to become even more important for payers and providers as the prevalence of end-stage knee osteoarthritis increases alongside the demand for cost-efficient options for treatment.
This two-center study demonstrated that patients who underwent Mako Partial Knee surgery had 100% survivorship at 36.3 months and a 92.5% satisfaction rate with their lateral UKA.
This study compared total and rate of caloric energy expenditure between conventional TKA and Mako Total Knee between a high-volume veteran surgeon and a lower volume, less experienced surgeon. The study demonstrated that while the rate of energy expenditure did not vary between CTKA and RTKA for the low volume surgeon, it did vary significantly for the high-volume surgeon. Additionally, RTKA took longer and increased total energy expenditure, but one less operating room assistant was needed.
The studies summarized in this scientific exhibit demonstrated that at a minimum 2-year follow-up, the novel, additively manufactured cementless titanium baseplates have demonstrated low migration, equivalent pain and blood loss to cemented, excellent survivorship and post-operative functional outcomes.
The study discussed in this podium presentation demonstrated that, at latest follow-up, revision THA with the MDM construct provided a low rate of revision in a cohort with instability, namely 2.9%, with good functional improvement. Recurrent instability following use of MDM in revision THA was associated with retention of the acetabular component, likely due to cup malposition.
References:
Dr. Roche is a paid-consultant of Stryker. The opinions expressed by Dr. Roche are those of Dr. Roche and not necessarily those of Stryker. Individual experiences may vary.
A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. The products depicted are CE marked according to the Medical Device Directive 93/42/EEC. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of any of Stryker’s products in your area.
Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Mako, Stryker. All other trademarks are trademarks of their respective owners or holders.
MKOSYM-COM-33_20365